Sleeve Gastrectomy Beat GLP-1s on Two-Year Cost by $12,794 in a Study Intuitive Surgical Funded
The cost gap rests on drug prices that have already moved, in a study whose funder sells surgical systems.
By subject
Tuznue Won Brazil Approval a Month After Its Plant Passed Anvisa Inspection, Nearly 20 Months After Filing
In Brazil the constraint on Prestige’s Herceptin biosimilar was not the dossier. It was the factory inspection.
Merck Is Taking a $400 Million Charge for a Preclinical KRAS G12D Drug After Backing Off Revolution
Merck is buying into KRAS G12D at the start line, well behind the company it reportedly tried to buy in January.
Bahrain Licensed Foundayo Six Months After the FDA as Lilly Takes Its Oral GLP-1 Global
Bahrain is small. The move matters as evidence of the global rollout Lilly argued a small-molecule GLP-1 would allow.
CMS Counted 450 Medicaid Quality Reporting Requirements for 260 Measures, and 37 States Pledged to Streamline Them
The pledge sets a direction without a single measure, target or date. The lever that will matter is managed care procurement.
AbbVie Largely Dropped Its Constitutional Case but Still Says Botox Is Plasma-Derived and Exempt
Constitutional challenges to Medicare negotiation have failed repeatedly. AbbVie is now betting on the definition of its product.
Europe Approved Leriglitazone for Boys With cALD Two Years After the EMA Recommended Refusal
A drug the EMA refused two years ago is now approved, on a narrow label and under exceptional circumstances, with Europe first.
Genentech Bets $1.5B+ on Earendil’s Bispecifics With $55M Upfront
The one clean upfront among this week’s discovery deals, and Earendil keeps more of the early clinical risk than most.
Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront
QuickDeal read/Deals Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront Athithi Verma· 24 September 2026· 2 min read· Synopulse InnoCare Pharma, listed in Hong Kong and Shanghai, said on 24 September 2026 that it has signed a strategic research collaboration and licence agreement with Eli Lilly. InnoCare will use its discovery platform … Read more
Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment
Henlius bought a switch, not a molecule, and the deal discloses no dollar figure at all, not even a headline total.